(19)
(11) EP 2 156 828 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.07.2015 Bulletin 2015/29

(45) Mention of the grant of the patent:
01.04.2015 Bulletin 2015/14

(21) Application number: 09168344.1

(22) Date of filing: 20.08.2009
(51) International Patent Classification (IPC): 
A61K 31/00(2006.01)
A61P 25/30(2006.01)
 A61K 31/485(2006.01)
A61P 25/36(2006.01)

(54)

Method and dosage regimens for eliminating an opioid substance in blood

Verfahren und Dosierpläne zum Eliminieren einer Opioidsubstanz im Blut

Procédé et régimes de dosage pour supprimer une substance opioïde dans le sang

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 20.08.2008 US 195143

(43) Date of publication of application:
24.02.2010 Bulletin 2010/08

(73) Proprietors:
  • Slater, Kenneth
    Manchester MA 01944 (US)
  • Richardson, Brenda
    Manchester MA 01944 (US)
  • Sawyer, Kenneth
    Cushing ME 04569 (US)
  • Chang, Wei-wei
    Boston MA 02115 (US)

(72) Inventors:
  • Slater, Kenneth C.
    Manchester, MA 01944 (US)
  • Richardson, Brenda E.
    Manchester, MA 01944 (US)
  • Connors, Scott M.
    Methuen, MA 01844 (US)
  • Chang, Wei-wei
    Boston, MA 02115 (US)

(74) Representative: Richaud, Fabien et al
Murgitroyd & Company Immeuble Atlantis 55, Allée Pierre Ziller
06560 Valbonne
06560 Valbonne (FR)


(56) References cited: : 
CA-A1- 2 621 575
   
  • BICKEL W K ET AL: "Effects of adding behavioral treatment to opioid detoxification with buprenorphine" JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, AMERICAN PSYCHOLOGICAL ASSOCIATION (PSYCARTICLES), vol. 65, no. 5, 1 January 1997 (1997-01-01), pages 803-810, XP009103398 ISSN: 0022-006X
  • AMASS L ET AL: "A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification" JOURNAL OF ADDICTIVE DISEASES, HAWORTH PRESS, BINGHAMTON, NY, US, vol. 13, no. 3, 1 January 1994 (1994-01-01), pages 33-45, XP009103405 ISSN: 1055-0887
  • BECKER A B ET AL: "Gradual dose taper following chronic buprenorphine" AMERICAN JOURNAL OF ADDICTIONS, AMERICAN PSYCHIATRIC PRESS, WASHINGTON, DC, US, vol. 10, no. 2, 1 January 2001 (2001-01-01), pages 111-121, XP009103399 ISSN: 1055-0496
  • JOHNSON ROLLEY E ET AL: "Buprenorphine: how to use it right" DRUG AND ALCOHOL DEPENDENCE, ELSEVIER SCIENTIFIC PUBLISHERS, IR, vol. 70, no. 2 Suppl, 21 May 2003 (2003-05-21), pages S59-S77, XP002488889 ISSN: 0376-8716
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).